Gram-negative bacteria, particularly Acinetobacter baumannii, pose a significant public health risk due to their high antibiotic resistance. Zosurabalpin, an antibiotic being developed by Roche, is set to enter phase 3 trials, marking a potential breakthrough in antibiotic treatment. Gram-negative bacteria’s dual outer membrane, fortified by lipopolysaccharides, makes them particularly resilient against treatments, complicating care for already vulnerable patients. The development of zosurabalpin could represent the first new class of antibiotics targeting these bacteria in over 50 years, aiming to restore effective treatment options for severe infections.
Gram-negative bacteria possess a robust outer membrane that hinders antibiotic access, contributing to their resistance and posing significant challenges in treating infections, particularly in vulnerable patients.
The introduction of zosurabalpin could mark a transformative change in the fight against Gram-negative bacteria, being the first new antibiotic class targeted at this group in over 50 years.
Collection
[
|
...
]